Clovis ovarian cancer drug rucaparib dubbed 'breakthrough'

The FDA has granted breakthrough therapy status to Clovis Oncology investigational agent rucaparib as monotherapy to treat advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA (gBRCA) and somatic BRCA (sBRCA) mutations.

The FDA has granted breakthrough therapy status to Clovis Oncology investigational agent rucaparib as monotherapy to treat advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA (gBRCA) and somatic BRCA (sBRCA) mutations.

Shares of Clovis jumped 12%, or $8.34, in after-hours trading on 6 April.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category